The Hartford Courant takes a close look at Boehringer Ingelheim's R&D work underway in Connecticut. While other Big Pharma companies have been cutting R&D efforts, Boehringer has been beefing up its research staff every year over the past three years. It currently has 1,300 staffers working in the state, and it plans to open a new building and hire even more in 2009.
"Being a private company, it is different," Phil Vickers, senior vice president and head of research for Boehringer in Ridgefield tells the Courant. "It allows us to implement longer-term strategies for research."
- read the report [1] in the Hartford Courant
Related Articles:
Boehringer boasts of late-stage drug potential [2]
Boehringer wins approval in anti-clotting drug race [3]
Boehringer Ingelheim - Top 13 Advertising Budgets [4]
Links:
[1] http://www.courant.com/business/hc-ctinc1009.artoct09,0,3994256.story?track=rss
[2] http://www.fiercebiotech.com/story/boehringer-boasts-of-late-stage-drug-potential/2008-04-08
[3] http://www.fiercebiotech.com/story/boehringer-wins-approval-in-anti-clotting-drug-race/2008-03-27
[4] http://www.fiercepharma.com/special-reports/boehringer-ingelheim-top-13-advertising-budgets